SINGAPORE (June 1): Singapore eDevelopment (SeD) announced on Monday that its wholly-owned subsidiary Impact Biomedical’s suite of antiviral and medical technologies, which is co-owned by its scientific research partner, Global Research and Discovery Group Sciences (GRDG Sciences), is valued at $1.97 billion.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply